liraglutide glp 1 analogue GLP-1 and selected FDA-approved GLP-1 analogs. (A) GLP-1 [4], (B) Lymphatic uptake of the lipidated

It fights inflammation

Extended-release exenatide (Bydureon BCise) has an apparent terminal half-life of approximately 2 weeks due to its depot formulation, with drug concentrations potentially persisting for 8-10 weeks after discontinuation

This can lead to confounding by indication, or channelling bias, meaning that the exposure to the drugs being tested are influenced by patients characteristics or comorbidities and such characteristics then drive differential outcome more than the drugs themselves

Stay away from strong smells

Appetite suppression increases, leading to lower caloric intake

It remains unclear whether these drugs are beneficial in people with anxiety or depression who do not also have obesity or T2D, which also warrants further investigation